Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by ronrydellon Jul 31, 2013 9:26am

561 Views

Post# 21640952

RE:RE:RE:RE:RE:RE:RE:RE:NEW Conversation With Sarah

The market is currently telling us we'll have an unfavorable outcome. We still have a substantial market cap for a drug that is producing no revenue and won't for a long time regardless of Sept 2 results. That being said..if we're down to the .20-.30 cent range by mid to late August this could be a good play, with a good report on Sept 2 bringing us back to a buck or more.

The gamble,and hope still continues.......

Bullboard Posts

High-growth stock Happy Belly opens first Rosie's Burgers in Alberta